Torquetenovirus Serum Load and Long-Term Outcomes in Renal Transplant Recipients.
immunosuppressed host
immunosuppression
outcome
renal transplantation
torquetenovirus
transplantation
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Feb 2020
06 Feb 2020
Historique:
received:
29
12
2019
revised:
23
01
2020
accepted:
04
02
2020
entrez:
12
2
2020
pubmed:
12
2
2020
medline:
12
2
2020
Statut:
epublish
Résumé
Following transplantation, patients must take immunosuppressive medication for life. Torquetenovirus (TTV) is thought to be marker for immunosuppression, and TTV-DNA levels after organ transplantation have been investigated, showing high TTV levels, associated with increased risk of infections, and low TTV levels associated with increased risk of rejection. However, this has been investigated in studies with relatively short follow-up periods. We hypothesized that TTV levels can be used to assess long term outcomes after renal transplantation. Serum samples of 666 renal transplant recipients were tested for TTV DNA. Samples were taken at least one year after renal transplantation, when TTV levels are thought to be relatively stable. Patient data was reviewed for graft failure, all-cause mortality and death due to infectious causes. Our data indicates that high TTV levels, sampled more than one year post-transplantation, are associated with all-cause mortality with a hazard ratio (HR) of 1.12 (95% CI, 1.02-1.23) per log
Identifiants
pubmed: 32041187
pii: jcm9020440
doi: 10.3390/jcm9020440
pmc: PMC7073853
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Healthy Aging Grant
ID : HAP2017-1-299
Références
PLoS One. 2015 Apr 20;10(3):e0122975
pubmed: 25894323
J Heart Lung Transplant. 2017 Mar;36(3):366-368
pubmed: 27876413
Transplantation. 2017 Feb;101(2):360-367
pubmed: 27525643
Transplant Rev (Orlando). 2019 Jul;33(3):137-144
pubmed: 30981537
Rev Med Virol. 2010 Nov;20(6):392-407
pubmed: 20925048
PLoS One. 2016 Sep 20;11(9):e0162278
pubmed: 27649571
Biochem Biophys Res Commun. 1997 Dec 8;241(1):92-7
pubmed: 9405239
Sci Rep. 2018 Oct 19;8(1):15490
pubmed: 30341363
Transplant Proc. 2005 Jun;37(5):2044-7
pubmed: 15964334
Virol J. 2014 May 20;11:96
pubmed: 24884576
J Virol. 1999 Nov;73(11):9604-8
pubmed: 10516070
J Virol. 2003 Feb;77(4):2418-25
pubmed: 12551979
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Med Virol. 2019 Apr 19;:
pubmed: 31002743
Am J Transplant. 2012 Feb;12(2):388-99
pubmed: 22081892
Am J Clin Nutr. 2016 Dec;104(6):1703-1711
pubmed: 27935524
Clin Microbiol Infect. 2016 Jul;22(7):589-93
pubmed: 27093875
Am J Transplant. 2004 Mar;4(3):378-83
pubmed: 14961990
Sci Rep. 2017 Oct 27;7(1):14264
pubmed: 29079835
Transpl Int. 2008 Oct;21(10):972-9
pubmed: 18564988
J Infect Dis. 2018 Sep 8;218(8):1191-1199
pubmed: 30007341
Intervirology. 1999;42(2-3):196-204
pubmed: 10516475
J Infect. 2019 Jul;79(1):56-60
pubmed: 31100359
Virology. 2009 Nov 25;394(2):235-42
pubmed: 19765789
J Clin Virol. 2018 Aug;105:118-127
pubmed: 29957546
J Med Virol. 2000 Aug;61(4):455-61
pubmed: 10897063
J Infect Dis. 2019 May 24;219(12):1934-1939
pubmed: 30668796
Arch Virol. 2015 Apr;160(4):893-908
pubmed: 25680568
Am J Transplant. 2019 Apr;19(4):1139-1149
pubmed: 30346659
Am J Transplant. 2009 Mar;9(3):527-35
pubmed: 19191769
PLoS One. 2014 Jun 11;9(2):e98819
pubmed: 24919177
Open Forum Infect Dis. 2018 Mar 06;5(4):ofy050
pubmed: 29644247
J Heart Lung Transplant. 2014 Mar;33(3):320-3
pubmed: 24559947
J Gen Virol. 2000 Dec;81(Pt 12):2949-2958
pubmed: 11086126
J Infect Dis. 2014 Jan 15;209(2):247-54
pubmed: 23922368